Strategies for Treatment of Thyroid Cancer

被引：4

作者：

Yadav, Deepika ^{[1
]}

Sharma, Pramod Kumar ^{[1
]}

Malviya, Rishabha ^{[1
]}

Mishra, Prem Shankar ^{[1
]}

机构：

[1] Galgotias Univ, Sch Med & Allied Sci, Dept Pharm, Greater Noida, Uttar Pradesh, India

来源：

CURRENT DRUG TARGETS | 2023年 / 24卷 / 05期

关键词：

Thyroid cancer; radioactive iodine; molecular therapy; ablation treatment; thyroidectomy; novel target therapy; RET/PTC ONCOGENE ACTIVATION; PHASE-II TRIAL; RET PROTOONCOGENE; PAPILLARY CARCINOMAS; CURRENT DIAGNOSIS; KINASE INHIBITOR; HIGH-FREQUENCY; RAS; REARRANGEMENTS; TUMORS;

D O I：

10.2174/1389450124666230222093308

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

More people are diagnosed with thyroid cancer than any other endocrine tumor. Differentiated thyroid cancer is often treated by removing the thyroid gland (thyroidectomy), iodizing radiation, or inhibiting thyroid stimulating hormone (TSH). Advanced thyroid carcinomas are notoriously resistant to chemotherapy, thus the pursuit of alternative treatments is vital. The best methods for treating individuals with advanced nonmedullary and medullary thyroid carcinomas are discussed in this post. Numerous tyrosine kinase inhibitors and antiangiogenic inhibitors, two types of novel target therapy, have shown promise in studies for individuals with thyroid cancer. Both the positive and unfavourable outcomes of clinical studies of these drugs were addressed. The findings presented here are encouraging, but more study is required to establish whether or not this method is effective in the treatment of thyroid cancer.

引用

页码：406 / 415

页数：10

共 50 条

[41] Multi-targeted approach in the treatment of thyroid cancer [J].

Zarebczan, B. ;

Chen, H. .

MINERVA CHIRURGICA, 2010, 65 (01) :59-69

[42] Update on thyroid cancer treatment [J].

Regalbuto, Concetto ;

Frasca, Francesco ;

Pellegriti, Gabriella ;

Malandrino, Pasqualino ;

Marturano, Ilenia ;

Di Carlo, Isidoro ;

Pezzino, Vincenzo .

FUTURE ONCOLOGY, 2012, 8 (10) :1331-1348

[43] Sorafenib in the treatment of thyroid cancer [J].

Ferrari, Silvia Martina ;

Politti, Ugo ;

Spisni, Roberto ;

Materazzi, Gabriele ;

Baldini, Enke ;

Ulisse, Salvatore ;

Miccoli, Paolo ;

Antonelli, Alessandro ;

Fallahi, Poupak .

EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (08) :863-874

[44] Vandetanib for the Treatment of Thyroid Cancer [J].

Langmuir, P. B. ;

Yver, A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (01) :71-80

[45] The treatment of differentiated thyroid cancer [J].

Hubold, C. ;

Buchmann, I. ;

Lehnert, H. .

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2011, 136 (17) :891-895

[46] Modified transoral endoscopic thyroid surgery for treatment of thyroid cancer: operative steps and video [J].

Peng, Xiao-Wei ;

Li, Hui ;

Li, Zan ;

Zhou, Xiao ;

Song, Da-Jiang ;

Zhou, Bo ;

Lv, Chun-Liu ;

Peng, Wen .

GLAND SURGERY, 2017, 6 (06) :742-744

[47] RAS Mutations in Thyroid Cancer [J].

Howell, Gina M. ;

Hodak, Steven P. ;

Yip, Linwah .

ONCOLOGIST, 2013, 18 (08) :926-932

[48] Modeling Thyroid Cancer in the Mouse [J].

Zhu, X-G. ;

Cheng, S-Y. .

HORMONE AND METABOLIC RESEARCH, 2009, 41 (06) :488-499

[49] The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies [J].

Lirov, Roy ;

Worden, Francis P. ;

Cohen, Mark S. .

DRUGS, 2017, 77 (07) :733-745

[50] The Efficacy and Safety of Anlotinib in the Treatment of Thyroid Cancer: A Systematic Review [J].

Muntean, Calin ;

Solomon, Adelaida ;

Cipaian, Remus Calin ;

Vonica, Razvan Constantin ;

Butuca, Anca ;

Gaborean, Vasile ;

Faur, Ionut Flaviu ;

Feier, Catalin Vladut Ionut .

JOURNAL OF CLINICAL MEDICINE, 2025, 14 (02)

← 1 2 3 4 5 →